Literature DB >> 473381

Lymph node tuberculosis: a comparison of treatments 18 months after completion of chemotherapy.

I A Campbell, A J Dyson.   

Abstract

Ninety patients with lymph node tuberculosis were treated with either rifampicin and isoniazid or ethambutol and isoniazid for 18 months, supplemented by sheptomycin for the first two months. No differences emerged between the two regimens, either during treatment or during an 18 month post-chemotherapy follow-up. In 7% of patients lymph nodes enlarged transiently after the end of treatment and in 7% enlarged nodes persisted. No patient required further treatment. One patient was left with an intermittently discharging sinus in an operation scar.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 473381     DOI: 10.1016/0041-3879(79)90042-4

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  6 in total

1.  Short course chemotherapy for tuberculosis of lymph nodes: a controlled trial. British Thoracic Society Research Committee.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-13

2.  Trends in tuberculosis.

Authors:  K M Citron
Journal:  Postgrad Med J       Date:  1984-03       Impact factor: 2.401

Review 3.  Chemotherapy of tuberculosis in children.

Authors:  P Ramachandran
Journal:  Indian J Pediatr       Date:  1982 May-Jun       Impact factor: 1.967

4.  Short course chemotherapy for tuberculous lymphadenitis in children.

Authors:  M S Jawahar; S Sivasubramanian; V K Vijayan; C V Ramakrishnan; C N Paramasivan; V Selvakumar; S Paul; S P Tripathy; R Prabhakar
Journal:  BMJ       Date:  1990 Aug 18-25

5.  Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

6.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.